Micromet

Micromet Inc. develops innovative antibody-based therapies primarily for cancer treatment. The company’s core product is its proprietary BiTE (Bispecific T-cell Engager) platform, which engineers antibodies with an 'extra molecular hook' capable of binding both cancer cells and T-cells. This unique bi-specificity directs the body's immune effector cells to target and destroy malignant cells, representing a novel approach to immuno-oncology with applications across various cancer types.